生物Nxt 快速获得了美国专利,用于治疗多发性硬化症的亚舌性克拉迪宾治疗,BNT23001,预计将在912个月内作出决定. BioNxt fast-tracked a U.S. patent for its sublingual cladribine treatment, BNT23001, for multiple sclerosis, with a decision expected in 9–12 months.

BioNxt Solutions Inc. 在美国完成了一项快速专利申请,用于其用于治疗多发性硬化症和其他神经自动免疫条件的Cladribine(BNT23001)亚语言薄膜薄膜薄膜版专利申请。 BioNxt Solutions Inc. has completed a fast-track patent filing in the U.S. for its sublingual thin-film version of cladribine, BNT23001, intended to treat multiple sclerosis and other neurological autoimmune conditions. 提交申请是快速审查方案的一部分,可在9-12个月内作出最后决定。 The filing, part of an expedited review program, could lead to a final decision within 9–12 months. 该公司还在主要的全球市场上寻求专利批准,欧洲和欧亚专利局发出了积极信号。 The company is also pursuing patent approvals in major global markets, with positive signals from European and Eurasian patent offices. 舌下给药方法旨在提高药物吸收、起效速度和患者依从性，特别是对于那些有吞咽困难或喜欢非注射选择的人。 The sublingual delivery method aims to improve drug absorption, speed of onset, and patient adherence, particularly for those with swallowing difficulties or who prefer non-injectable options. BioNxt侧重于先进的药物交付技术,继续推进监管和商业化努力,主要在欧洲,并被列入若干国际交流名单。 BioNxt, focused on advanced drug delivery technologies, continues advancing regulatory and commercialization efforts, primarily in Europe, and is listed on several international exchanges.